A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Parkinson's Disease
Interventions
DRUG

IPX066

experimental product

DRUG

CLE

active comparator

Trial Locations (24)

163

IRCCS San Raffaele Pisana, Roma

11725

Parkinson's Disease and Movement Disorders Center of Long Island, Commack

12401

Kingston Neurological Associates, Kingston

13385

Service de neurologie-Hôpital de la Timone-, Marseille

23456

Sentara Neurological Associates, Virginia Beach

28832

Praxis für Neurologie, Psychiatrie und Psychotherapie Achim, Achim

33136

UM Movement Disorders Center, Miami

33606

USF Parkinson's and Movement Disorders Center, Tampa

33980

Charlotte Neurological Services, Port Charlotte

36057

Casa di Cura Villa Margherita, Arcugnano

44805

Praxis Dres. Bitter/Schumann, Bochum

45219

University Neurology, Inc, Cincinnati

48025

Quest Research Institute, Bingham Farms

58100

Ospedale della Misericordia, Grosseto

63003

Hôpital Gabriel Montpied-Service de Neurologie A-, Clermont-Ferrand

66013

Dipartimento di Oncologia e Neuroscienze, Università G. D'Annunzio, Chieti

81675

Klinikum rechts der Isar der Technischen Universität München, München

89081

RKU, Neurologische Klinik der Universität Ulm, Ulm

89102

University Health Systems, Las Vegas

93720

Margolin Brain Institute, Fresno

94085

The Parkinson's Institute in Sunnyvale, Sunnyvale

98034

Booth Gardner Parkinson's Care Center, Kirkland

07646

Klinik für Neurologie, Stadtroda, Stadtroda

03043

San Raffaele Cassino, San Raffaele Cassino,, Cassino

Sponsors
All Listed Sponsors
lead

Impax Laboratories, LLC

INDUSTRY